Injection site reaction when to worry: who to call and what published cases showed
Injection site reaction when to worry starts with the numbers. In Sweden, Germany and Spain, 112 is the emergency number. Sweden also has Giftinformationscentralen for poisoning questions. Germany has 116117 for medical help after ordinary practices close, if the case is not life-threatening. Spain has a poison line on 91 562 04 20.
Which emergency and poison numbers come first?
| Country | Service | Number | What the service page says |
|---|---|---|---|
| Sweden | Emergency number | 112 | SOS Alarm says 112 is Sweden's and the EU's emergency number, for situations where someone needs urgent help. |
| Sweden | Giftinformationscentralen, acute poisoning | 112, ask for Giftinformation | Giftinformationscentralen lists this route for acute poisoning questions around the clock. |
| Sweden | Giftinformationscentralen, less acute poisoning | 010-456 6700 | Giftinformationscentralen lists this number for the public around the clock. |
| Sweden | Healthcare advice | 1177 | 1177 says its national phone line is healthcare advice around the clock, and says life-threatening cases go to 112. |
| Germany | Emergency number | 112 | 116117's own site says life-threatening cases go to emergency services on 112. |
| Germany | Medical on-call service | 116117 | 116117 says it is available 24 hours a day, seven days a week, for cases that are not life-threatening. |
| Germany | Poison information centres | See the BfR directory below | The BfR lists regional Giftinformationszentren rather than one national poison number. |
| Spain | Emergency number | 112 | Spain's Punto de Acceso General says 112 covers emergency services throughout Spain and is free from fixed and mobile phones. |
| Spain | Poison information line | 91 562 04 20 | Spain's Ministry of Justice says the toxicology information service is available 24 hours a day, every day of the year. |
Source, claim checked 20 August 2026:
- Sweden: SOS Alarm 112, Giftinformationscentralen contact page and 1177 when you call.
- Germany: 116117 and BfR Giftinformationszentren.
- Spain: Spain 112 and Spain's toxicology information service.
Which German poison-information centres does BfR list?
The BfR directory is headed as the directory of Germany's Giftinformationszentren, designated by the federal states under Chemicals Act section 16e(3). The directory gives these phone lines:
| Location | Centre | Phone line listed by BfR |
|---|---|---|
| Berlin | Giftnotruf der Charité, Universitätsmedizin Berlin, Campus Mitte | 030 - 192 40 |
| Bonn | Informationszentrale gegen Vergiftungen am Universitätsklinikum Bonn | 0228 - 1924 0 |
| Erfurt | Giftnotruf Erfurt, for Mecklenburg-Vorpommern, Saxony, Saxony-Anhalt and Thuringia | 0361 - 7307 30 |
| Freiburg | Vergiftungs-Informations-Zentrale, Universitätsklinikum Freiburg | 0761 - 1924 0 |
| Göttingen | Giftinformationszentrum-Nord, for Bremen, Hamburg, Lower Saxony and Schleswig-Holstein | 0551 - 1924 0 |
| Mainz | Giftinformationszentrum Mainz, for Rhineland-Palatinate, Hesse and Saarland | 06131 - 1924 0 |
| Munich | Giftnotruf München, TUM Klinikum Rechts der Isar | 089 - 1924 0 |
The directory groups some centres by federal state and lists others by city. It is not a routing tool for a specific address. In a life-threatening emergency, 116117 and the Swedish, German and Spanish emergency pages point to 112.
Source, claim checked 20 August 2026: BfR Giftinformationszentren directory.
What did people in the published cases present with?
These are published case reports. They describe specific patients, not a checklist for an injection site reaction.
Italy. A 31-year-old woman injected a product she believed was semaglutide, bought from an unregulated online marketplace. She developed severe low blood sugar and coma. The vial was analysed afterwards and insulin was identified instead of semaglutide. European Journal of Hospital Pharmacy 2025, PMID 41125326.
Netherlands. Two patients were admitted in coma after injecting semaglutide obtained without a prescription. They had severe low blood sugar, low potassium and low body temperature. The report gives the cause as intoxication with synthetic insulin. Up to two days of continuous glucose infusion were needed. Nederlands Tijdschrift voor Geneeskunde 2026, PMID 42390457.
Belgium. An 18-year-old presented with euglycemic ketoacidosis after using counterfeit semaglutide for weight loss. The product was not analysed in the paper, so this case does not identify what was in the product. Cureus 2026, PMID 41773123, DOI 10.7759/cureus.102627.
European adverse-event reports. Across 234 EudraVigilance reports of suspected counterfeit semaglutide from 1 January 2018 to 31 December 2025, the most frequently reported reactions were vomiting, nausea and low blood sugar. The authors classify 89.3% of the suspected adverse drug reactions as serious. Frontiers in Pharmacology 2026, PMID 42137313.
That database holds reports that were made. The paper states that the number of exposed patients is unknown, so incidence and other risk measures cannot be calculated from it. It also states that some reports may be suspected rather than confirmed counterfeit cases, while other counterfeit exposures may not have been recognised or reported.
Source, claim checked 20 August 2026: source notes for PMID 41125326, PMID 42390457, PMID 41773123 and PMID 42137313.
What do treatment data show about injection-site symptoms?
The nearest published survey to this site's readers asked 366 men who inject image- and performance-enhancing drugs about treatment. It asked whether they had ever had treatment for an injection-site symptom. The question was put to the men who reported that symptom, so the counts below are out of those groups rather than out of all 366.
| Had ever had treatment | Redness, tenderness and swelling (155 men) | Abscess, sore or open wound (25 men) |
|---|---|---|
| Yes | 27 - 17% | 19 - 76% |
The same table records where that treatment came from. People could name more than one source, so the columns total more than 100%.
| Source | Of the 27 with redness, tenderness and swelling | Of the 19 with abscess, sore or open wound |
|---|---|---|
| General practitioner | 59% | 32% |
| Accident and Emergency or walk-in clinic | 48% | 47% |
| Self-treatment | 48% | 26% |
| Needle-and-syringe programme | 22% | 5% |
| Other source | 22% | 0% |
This was self-reported, UK, published in 2015, and not a peptide-user population. Image- and performance-enhancing drug use is dominated by anabolic steroids. The authors state that the representativeness of the sample was impossible to measure and that caution is needed when generalising from it.
Source, claim checked 20 August 2026: Hope VD et al., Epidemiology and Infection 2015, PMID 24713416, Table 3.
What can and cannot an injection-site page show?
A web page cannot examine an injection site. It also cannot test what was in a vial.
Published cases can show what happened to named patients after use of products sold as semaglutide. They cannot show that the same thing is happening to someone else.
The treatment survey can show that some men with redness, tenderness and swelling had treatment and that some named self-treatment. It cannot say what proportion of peptide users have the same symptoms.
Endotoxin is a separate issue from live bacteria. A 2025 depyrogenation paper states that endotoxin in the bloodstream can cause fever and, in severe cases, endotoxemia and bacteraemia that can lead to death. That paper is about manufacturing ampoules, not grey-market peptide vials.
Source, claim checked 20 August 2026: Rashed AM et al., Journal of Pharmaceutical Sciences 2025, PMID 40122208.
What information may help a clinician?
The published cases above all record what the patient had taken. In the Italian case, the vial itself was analysed, and that analysis identified insulin in place of semaglutide.
If the vial, packaging or batch number still exists, that information may be useful. A blood test cannot quickly reconstruct the label, the seller's description or the batch details.
The related pages are talking to a doctor, sterility and infection and what is in the vial.
What do these cases not prove?
They do not prove that the published outcomes are typical. A case report is written because something happened that was worth publishing.
They do not prove that a lump, pain, swelling, redness or warmth at an injection site has one specific cause. Those words are search terms and symptoms; they are not a diagnosis.
They do not turn a spontaneous-reporting database into an incidence rate. The EudraVigilance paper says the number of exposed patients is unknown.
The shared vial and evidence overview links to related questions about tests, certificates and calculations.